WO2009005002A1 - キノロン誘導体 - Google Patents

キノロン誘導体 Download PDF

Info

Publication number
WO2009005002A1
WO2009005002A1 PCT/JP2008/061733 JP2008061733W WO2009005002A1 WO 2009005002 A1 WO2009005002 A1 WO 2009005002A1 JP 2008061733 W JP2008061733 W JP 2008061733W WO 2009005002 A1 WO2009005002 A1 WO 2009005002A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen atom
independently represent
different
same
optionally substituted
Prior art date
Application number
PCT/JP2008/061733
Other languages
English (en)
French (fr)
Inventor
Hiroyuki Nakahira
Hitoshi Hochigai
Masahiro Takamura
Yohei Ikuma
Original Assignee
Dainippon Sumitomo Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co., Ltd. filed Critical Dainippon Sumitomo Pharma Co., Ltd.
Publication of WO2009005002A1 publication Critical patent/WO2009005002A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

　本発明は、レニン阻害剤として有用な式（Ｉ）の化合物、またはその薬学上許容される塩を提供する。 ［式中、Ｒ１ａは、置換されてもよいＣ１－６アルキル基等であり；Ｒ１ｂおよびＲ１ｅは、各々独立して、同一または異なって、水素原子、ハロゲン原子等であり；Ｒ１ｃおよびＲ１ｄは、各々独立して、同一または異なって、水素原子、ハロゲン原子等であり；Ｒ１ｆは、水素原子等であり；Ｒ２は、置換されてもよいＣ１－６アルキル基等であり；Ｒ３ａ、Ｒ３ｂ、Ｒ３ｃおよびＲ３ｄは、各々独立して、同一または異なって、基：－Ａ－Ｂ（Ａは、単結合等であり、Ｂは、水素原子等である。）等であり；ｎは、０等である。］
PCT/JP2008/061733 2007-06-29 2008-06-27 キノロン誘導体 WO2009005002A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-173565 2007-06-29
JP2007173565A JP2010208947A (ja) 2007-06-29 2007-06-29 キノロン誘導体

Publications (1)

Publication Number Publication Date
WO2009005002A1 true WO2009005002A1 (ja) 2009-01-08

Family

ID=40226048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061733 WO2009005002A1 (ja) 2007-06-29 2008-06-27 キノロン誘導体

Country Status (2)

Country Link
JP (1) JP2010208947A (ja)
WO (1) WO2009005002A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129467A1 (en) * 2009-05-04 2010-11-11 Plexxikon, Inc. Compounds and methods for inhibition of renin, and indications therefor
WO2010150840A1 (ja) 2009-06-24 2010-12-29 大日本住友製薬株式会社 Ｎ－置換－環状アミノ誘導体
US8389511B2 (en) 2007-12-19 2013-03-05 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic heterocyclic derivative
US8466282B2 (en) 2008-06-19 2013-06-18 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
CN108299397A (zh) * 2018-03-21 2018-07-20 佳木斯大学附属第医院 一种用于降血压的活性药物及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013088452A2 (en) 2011-11-11 2013-06-20 Sun Pharma Advanced Research Company Ltd. Quinoline derivatives as renin inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05501255A (ja) * 1989-10-14 1993-03-11 ジョン・ワイス・アンド・ブラザー・リミテッド 複素環式化合物
JPH08311066A (ja) * 1995-05-16 1996-11-26 Yamanouchi Pharmaceut Co Ltd 新規な４−オキソキノリンカルボキサミド誘導体又はその塩
JP2006522793A (ja) * 2003-04-10 2006-10-05 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 高血圧治療のためのレニン阻害剤としてのピペリジン誘導体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05501255A (ja) * 1989-10-14 1993-03-11 ジョン・ワイス・アンド・ブラザー・リミテッド 複素環式化合物
JPH08311066A (ja) * 1995-05-16 1996-11-26 Yamanouchi Pharmaceut Co Ltd 新規な４−オキソキノリンカルボキサミド誘導体又はその塩
JP2006522793A (ja) * 2003-04-10 2006-10-05 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 高血圧治療のためのレニン阻害剤としてのピペリジン誘導体

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389511B2 (en) 2007-12-19 2013-03-05 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic heterocyclic derivative
US8466282B2 (en) 2008-06-19 2013-06-18 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8664380B2 (en) 2008-06-19 2014-03-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9045436B2 (en) 2008-06-19 2015-06-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9221836B2 (en) 2008-06-19 2015-12-29 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2010129467A1 (en) * 2009-05-04 2010-11-11 Plexxikon, Inc. Compounds and methods for inhibition of renin, and indications therefor
WO2010150840A1 (ja) 2009-06-24 2010-12-29 大日本住友製薬株式会社 Ｎ－置換－環状アミノ誘導体
US8658639B2 (en) 2009-06-24 2014-02-25 Dainippon Sumitomo Pharma Co., Ltd N-substituted-cyclic amino derivative
CN108299397A (zh) * 2018-03-21 2018-07-20 佳木斯大学附属第医院 一种用于降血压的活性药物及其制备方法
CN108299397B (zh) * 2018-03-21 2019-01-29 佳木斯大学附属第一医院 一种用于降血压的活性药物及其制备方法

Also Published As

Publication number Publication date
JP2010208947A (ja) 2010-09-24

Similar Documents

Publication Publication Date Title
WO2008136457A1 (ja) 含窒素芳香族誘導体
WO2009078481A1 (ja) 二環性へテロ環誘導体
WO2009005002A1 (ja) キノロン誘導体
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2008083252A3 (en) Methods of use for cyclopamine analogs
AU2015200390A1 (en) Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
RS54101B1 (en) A CYCLOPROPAN UNIT
WO2006049835A3 (en) Indole and benzimidazole derivatives
WO2009020140A1 (ja) アダマンチルウレア誘導体
WO2009054479A1 (ja) スピロ環化合物及びその医薬用途
WO2007084390A3 (en) Histone deacetylase inhibitors
WO2009042114A3 (en) Phenazine derivatives and uses thereof
WO2007062308A3 (en) Homo- and heterocyclic compounds suitable as cetp inhibitors
WO2007011626A3 (en) Histone deacetylase inhibitors
WO2007087416A3 (en) Methods of increasing oral bioavailability of tetracyclines
WO2004066920A3 (en) 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
WO2006066133A3 (en) Histone deacetylase inhibitors
WO2008048867A3 (en) Bicyclic heteroaromatic compounds
WO2008060476A3 (en) Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2012101011A3 (en) New aryl-benzocycloalkyl amide derivatives
WO2010066629A3 (en) Novel azaindoles
WO2009020137A1 (ja) アミノピラゾールアミド誘導体
WO2009098458A3 (en) Difluorobiphenylamide derivatives for the treatment of ocular hypertension
WO2009014217A1 (ja) 二環性ピロール誘導体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08790698

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08790698

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP